WWM
JAZZ icon

Willingdon Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Willingdon Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7
Closed -$1K – 461
2019
Q3 		$1K Buy
+7
New +$938 ﹤0.01% 430
2017
Q4 		– Sell
-93
Closed -$14K – 359
2017
Q3 		$14K Buy
+93
New +$14.1K 0.01% 207

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Willingdon Wealth Management's JAZZ Position: Q4 2019 in Review

Willingdon Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2019, closing a stake of 7 shares — an estimated $1K sold.

Willingdon Wealth Management first reported a position in JAZZ in Q3 2017 and held it in 2 quarters. The position peaked at $14K in Q3 2017. 446 funds tracked by Wall St. Rank hold JAZZ as of Q4 2019.

  • Willingdon Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Willingdon Wealth Management sold 7 Jazz Pharmaceuticals shares in Q4 2019, an estimated $1K.
  • Willingdon Wealth Management first reported a position in Jazz Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Willingdon Wealth Management's Jazz Pharmaceuticals position peaked at $14K in Q3 2017.
  • 446 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.